- Home
- CARA
as 07-26-2024 4:00pm EST
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | STAMFORD |
| Market Cap: | 40.1M | IPO Year: | 2014 |
| Target Price: | $1.00 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Hold | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.26 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.24 - $3.45 | Next Earning Date: | 08-05-2024 |
| Revenue: | $16,938,000 | Revenue Growth: | -60.83% |
| Revenue Growth (this year): | -68.8% | Revenue Growth (next year): | 5.93% |
Stock Insider Trading Activity of Cara Therapeutics Inc. (CARA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Posner Christopher | CARA | PRESIDENT AND CEO | May 2 '24 | Sell | $0.75 | 3,936 | $2,952.00 | 176,585 | SEC Form 4 |
| Terrillion Scott | CARA | SEC'Y; CHIEF COMPLIANCE & G.C. | Apr 5 '24 | Sell | $0.83 | 2,753 | $2,284.99 | 88,247 | SEC Form 4 |
| Goncalves Joana | CARA | CHIEF MEDICAL OFFICER | Apr 5 '24 | Sell | $0.83 | 2,753 | $2,284.99 | 53,365 | SEC Form 4 |
| Posner Christopher | CARA | PRESIDENT AND CEO | Feb 29 '24 | Sell | $0.89 | 5,834 | $5,192.26 | 180,521 | SEC Form 4 |
| Goncalves Joana | CARA | CHIEF MEDICAL OFFICER | Feb 29 '24 | Sell | $0.89 | 3,293 | $2,930.77 | 56,118 | SEC Form 4 |
| Terrillion Scott | CARA | SEC'Y; CHIEF COMPLIANCE & G.C. | Feb 29 '24 | Sell | $0.89 | 3,293 | $2,930.77 | 91,000 | SEC Form 4 |
| Maynard Ryan D | CARA | CHIEF FINANCIAL OFFICER | Feb 8 '24 | Sell | $0.53 | 5,488 | $2,908.64 | 8,012 | SEC Form 4 |
| Terrillion Scott | CARA | SEC'Y; CHIEF COMPLIANCE & G.C. | Feb 8 '24 | Sell | $0.53 | 7,770 | $4,118.10 | 94,293 | SEC Form 4 |
| Posner Christopher | CARA | PRESIDENT AND CEO | Feb 8 '24 | Sell | $0.53 | 35,575 | $18,854.75 | 186,355 | SEC Form 4 |
| Goncalves Joana | CARA | CHIEF MEDICAL OFFICER | Feb 8 '24 | Sell | $0.53 | 7,770 | $4,118.10 | 59,411 | SEC Form 4 |
| Posner Christopher | CARA | PRESIDENT AND CEO | Feb 1 '24 | Sell | $0.55 | 4,981 | $2,739.55 | 221,930 | SEC Form 4 |
Latest Cara Therapeutics Inc. News
CARA Breaking Stock News: Dive into CARA Ticker-Specific Updates for Smart Investing
MT Newswires
16 days ago
Cara Therapeutics Explores Strategic Alternatives; Shares Rise Pre-Bell
GlobeNewswire
16 days ago
Cara Therapeutics Announces Exploration of Strategic Alternatives
MT Newswires
a month ago
Sector Update: Health Care Stocks Lean Lower Pre-Bell Thursday
MT Newswires
a month ago
Cara Therapeutics to Idle 70% Workforce, Explore Alternatives After Scrapping Notalgia Paresthetica Program
The Fly
a month ago
Chipotle, McDonald's initiated: Wall Street's top analyst calls
MT Newswires
a month ago
--HC Wainwright Downgrades Cara Therapeutics to Neutral From Buy
MT Newswires
a month ago
--Needham Downgrades Cara Therapeutics to Hold From Buy
MT Newswires
a month ago
Cara Therapeutics Discontinues NP Program After Drug Study Fails to Show Clinical Benefit -- Shares Drop
Compare CARA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CARA Cara Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.